D. E. Shaw & Co. Inc. Raises Position in REGENXBIO Inc. (NASDAQ:RGNX)

D. E. Shaw & Co. Inc. grew its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 15.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 63,377 shares of the biotechnology company’s stock after acquiring an additional 8,271 shares during the period. D. E. Shaw & Co. Inc. owned about 0.13% of REGENXBIO worth $490,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also modified their holdings of the company. Deutsche Bank AG lifted its holdings in REGENXBIO by 8.5% during the 4th quarter. Deutsche Bank AG now owns 200,375 shares of the biotechnology company’s stock worth $1,549,000 after buying an additional 15,722 shares during the last quarter. Corton Capital Inc. acquired a new stake in shares of REGENXBIO during the 4th quarter worth about $103,000. Cubist Systematic Strategies LLC purchased a new stake in REGENXBIO during the fourth quarter worth approximately $2,793,000. Brevan Howard Capital Management LP acquired a new position in REGENXBIO in the fourth quarter valued at approximately $318,000. Finally, Balyasny Asset Management L.P. increased its stake in REGENXBIO by 6.0% in the fourth quarter. Balyasny Asset Management L.P. now owns 1,187,102 shares of the biotechnology company’s stock valued at $9,176,000 after purchasing an additional 66,993 shares during the last quarter. Hedge funds and other institutional investors own 88.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on RGNX. The Goldman Sachs Group decreased their target price on REGENXBIO from $14.00 to $12.00 and set a “neutral” rating for the company in a research report on Thursday, April 17th. Wall Street Zen raised REGENXBIO from a “sell” rating to a “hold” rating in a report on Friday, March 7th. Chardan Capital restated a “buy” rating and set a $52.00 target price on shares of REGENXBIO in a research report on Thursday, March 20th. HC Wainwright reduced their price target on shares of REGENXBIO from $36.00 to $34.00 and set a “buy” rating for the company in a research report on Monday, March 17th. Finally, Raymond James assumed coverage on shares of REGENXBIO in a research note on Friday, February 7th. They set an “outperform” rating and a $27.00 price target for the company. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $31.63.

REGENXBIO Stock Performance

Shares of RGNX opened at $9.71 on Monday. REGENXBIO Inc. has a one year low of $5.04 and a one year high of $15.39. The stock’s fifty day moving average is $7.82 and its 200-day moving average is $7.99. The firm has a market capitalization of $487.05 million, a price-to-earnings ratio of -1.93 and a beta of 1.11.

REGENXBIO (NASDAQ:RGNX) last issued its quarterly earnings results on Monday, May 12th. The biotechnology company reported $0.12 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.41 by ($0.29). The firm had revenue of $89.01 million for the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative net margin of 283.19% and a negative return on equity of 70.65%. Analysts forecast that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.

Insider Activity

In other news, Director Kenneth T. Mills sold 20,602 shares of the business’s stock in a transaction on Monday, May 12th. The stock was sold at an average price of $7.91, for a total transaction of $162,961.82. Following the sale, the director now directly owns 475,103 shares of the company’s stock, valued at $3,758,064.73. The trade was a 4.16% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders own 12.79% of the company’s stock.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.